Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Neoplasms

Symptoms and General Pathology

Musculoskeletal Diseases

Skin and Connective Tissue Diseases

Immune System Diseases

Wounds and Injuries

Digestive System Diseases

Nutritional and Metabolic Diseases

Infections

Diseases and Abnormalities at or Before Birth

Rare Diseases

Kidney Diseases

Neoplasm Metastasis

Syndrome

Arthritis

Arthritis, Rheumatoid

Hyperthermia

Gastrointestinal Diseases

Amyloidosis

Fever

Nephrotic Syndrome

Nephrosis

Brucellosis

Familial Mediterranean Fever

Hereditary Autoinflammatory Diseases

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Neoplastic Processes

Proteostasis Deficiencies

Metabolic Diseases

NC-503 (Anti-amyloidotic (AA) Agent)

The main objective of this study is to evaluate the safety and efficacy of NC-503 compared to placebo in patients with secondary (AA) amyloidosis using a composite assessment of clinical improvement/worsening of both renal and gastrointestinal functions.

AA amyloidosis is associated with chronic inflammatory conditions (rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease), chronic infection (tuberculosis, osteomyelitis), and Familial Mediterranean Fever. Rheumatoid arthritis is the major cause of AA amyloidosis in Western Europe and North America. The most common clinical feature of AA amyloidosis is renal dysfunction manifested as nephrotic-range proteinuria or renal insufficiency at the time of diagnosis. End-stage renal failure is the cause of death in 40-60% of cases. Gastrointestinal involvement is also frequent and is usually manifested as chronic diarrhea, body weight loss and malabsorption. Enlargement of the liver and spleen may also occur in some patients. The median survival time from diagnosis varies from 2 to 8 years depending on the stage of the disease at time of diagnosis. The goal of the current therapy in AA amyloidosis is the control of the associated disease. However, the current approaches for the treatment of AA amyloidosis are unspecific, toxic, invasive, and not sufficiently effective in many cases. NC-503 was specifically designed to compete with the naturally occurring sulfated GAGs for the binding to amyloidogenic precursor proteins, and to inhibit amyloid deposition into tissues. The proposed therapy with NC-503 is based on the prevention of the amyloid fibril formation. The objective of this clinical phase II/III study is to determine the efficacy and safety of NC-503 compared to a placebo in patients suffering from secondary (AA) amyloidosis by the assessment of clinical improvement/ worsening of both renal and gastrointestinal functions.

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis

FDA Office of Orphan Products Development

Bellus Health Inc. - a GSK company

Spots Global Cancer Trial Database for secondary (aa) amyloidosis